PHC and Cyfuse Develop Breakthrough Technology for Commercializing 3D Cell Products
PHC Corporation, a subsidiary of PHC Holdings Corporation, and Cyfuse Biomedical K.K. have announced a significant milestone in the field of regenerative and cell therapy. The two companies have successfully developed a new production technology aimed at improving the commercialization of 3D cell products. This development is the result of a strategic collaboration and joint research between PHC and Cyfuse.
Advancements in 3D Cell Product Production
The newly developed production technology introduces a groundbreaking approach to real-time monitoring of 3D cell products, which are living cells organized into three-dimensional structures. Historically, monitoring the quality of these 3D cell constructs has been a challenge, but this new technology addresses that issue and ensures the stable production of high-quality cell products.
In this collaboration, Cyfuse utilized its proprietary Bio 3D Printing technology to manufacture 3D cell constructs, while it employed its in-line monitoring technology in its LiCellGrow™ cell expansion system. This system, currently under development, tracks the metabolic activity of the cell constructs. By combining Cyfuse’s advanced 3D printing technology with it’s in-line monitoring capabilities, the companies have achieved improved quality and stability of 3D cell products during their cultivation process.
Real-Time Monitoring of 3D Cell Products
One of the key features of the new production technology is the ability to monitor critical cell culture parameters in real time. For instance, glucose and lactate concentrations in the culture medium can be continuously measured, ensuring that the culture environment is optimized for cell growth. This precise control of glucose concentration is essential for maintaining the desired conditions for 3D cellular structures, such as those used in Cyfuse’s products.
This technology allows for automatic medium replacement based on the concentrations of glucose and lactate, improving the overall quality and stability of the 3D cell products. By keeping these critical parameters in check, the companies are able to ensure the consistency and reliability of the final products, which is crucial for the success of regenerative medicine and cell therapies.
The Circulation Cell Culture System: The Next Step
Building on this development, the corporations are now focused on developing the next-generation cell expansion system: a circulation cell culture system. This new device will integrate the innovative production technology, offering advanced capabilities in monitoring cell conditions and optimizing the manufacturing process in real time. The circulation cell culture system will be designed to identify critical process parameters during 3D cell product manufacturing, allowing for the fine-tuning of production conditions based on the state of the cells.
The goal of this system is to further improve the quality and stability of 3D cell products, making them more reliable for use in regenerative medicine. The corporations believe that this new system will play a pivotal role in enhancing the production of Cyfuse’s 3D cell products, ensuring they meet the rigorous standards required for clinical applications.
Presentation at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine
The development of this new production technology will be showcased at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine, taking place from March 20 to March 22, 2025, at Pacifico Yokohama in Japan. They will present their research findings through poster presentations, focusing on the ongoing development of the circulation cell culture system and the quality evaluation of Cyfuse’s 3D cell products cultured using this system.
This event will provide an opportunity for the companies to share their progress with the scientific community and receive feedback from experts in the regenerative medicine field.
Continuing Collaboration and Advancements
PHC and Cyfuse remain committed to advancing their joint research efforts to accelerate the practical application of these innovative production technologies. Both companies are working to expand the value chain within the rapidly growing field of regenerative and cell therapy. Through their collaboration, they aim to promote research, technological innovation, and the development of new products, including Cyfuse’s regenerative medicine solutions.
By strengthening their strategic partnership, PHC and Cyfuse are confident in their ability to drive growth and progress in the regenerative medicine sector. The companies are also focused on creating new opportunities for cell therapy applications, contributing to the ongoing evolution of regenerative medicine and cell-based therapies.
Conclusion
The partnership between the corporations marks a significant step forward in the commercialization of 3D cell products for regenerative and cell therapy applications. Through the development of real-time monitoring technology and the circulation cell culture system, the companies aim to create a more stable and efficient production process for 3D cell products, ultimately enhancing the quality and reliability of cell-based therapies.
With ongoing research and development, they are poised to make substantial contributions to the regenerative medicine field, improving patient outcomes and advancing the future of cell therapy.
https://www.phchd.com/jp/phc/news/2024/1001 (Japanese only)
About the Biomedical Division of PHC Corporation
Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO2 incubators and ultra-low temperature freezers.
www.phchd.com/global/phc
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group’s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com/global
About Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. (Securities Code: 4892, TSE Growth) is a regenerative medicine startup founded in 2010. Using its proprietary bio 3D printing technology, which creates three-dimensional tissues solely from cells without artificial scaffolds, the company develops innovative regenerative medicine products and sells Bio 3D printers, Regenova® and S-PIKE®.
For more information, please visit “CYCHANNEL” at www.cyfusebio.com/cychannel.
